Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 331 followers
Latest posts
Last updated about 2 hours ago
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised
about 2 hours ago
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of authorisation: 13/03/1997, Revision: 41, Status: Authorised
about 2 hours ago
Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of...
Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
about 2 hours ago
Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Date of...
Medicinal products for human use: monthly figures - April 2026
about 2 hours ago
Medicinal products for human use: monthly figures - April 2026
Human medicines European public assessment report (EPAR): Poherdy, pertuzumab, Date of authorisation: 23/04/2026, Status: Authorised
about 4 hours ago
Human medicines European public assessment report (EPAR): Poherdy, pertuzumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation: 23/07/2012, Revision: 36, Status: Authorised
about 5 hours ago
Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation...
Orphan designation: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one (futibatinib) Treatment of biliary tract cancer, 01/04/2019 Withdrawn
about 6 hours ago
Orphan designation: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one (futibatinib) Treatment of biliary tract cancer, 01/04/2019 Withdrawn
Orphan designation: S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Treatment of primary sclerosing cholangitis, 16/10/2017 Withdrawn
about 6 hours ago
Orphan designation: S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Treatment of primary sclerosing cholangitis, 16/10/2017 Withdrawn
Orphan designation: Humanised monoclonal antibody against P-selectin (crizanlizumab) Treatment of sickle cell disease, 09/08/2012 Withdrawn
about 6 hours ago
Orphan designation: Humanised monoclonal antibody against P-selectin (crizanlizumab) Treatment of sickle cell...
Orphan designation: N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt Treatment of acute myeloid leukaemia, 23/03/2009 Withdrawn
about 6 hours ago
Orphan designation: N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt Treatment of acute myeloid leukaemia, 23/03/2009...
Orphan designation: 5-Methyl-pyridine-2-sulfonic acid{6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt Treatment of aneurysmal subarachnoid haemorrhage, 12/12/2003 Withdrawn
about 6 hours ago
Orphan designation: 5-Methyl-pyridine-2-sulfonic acid{6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt Treatment of aneurysmal subarachnoid haemorrhage, 12/12/2003...
Orphan designation: oregovomab Treatment of ovarian cancer, 30/07/2002 Withdrawn
about 6 hours ago
Orphan designation: oregovomab Treatment of ovarian cancer, 30/07/2002 Withdrawn